After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for BioXcel Therapeutics Inc. (BTAI) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.02, or -0.59%, to $3.36. The BioXcel Therapeutics Inc. has recorded 11,919 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that BTAI: Strategic Reprioritization Underway..
BTAI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.38 and fluctuated between $3.4950 as its day high and $3.3200 as its day low. The current market capitalization of BioXcel Therapeutics Inc. is $90.45M. A total of 0.82 million shares were traded on the day, compared to an average of 3.00M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, BTAI has seen 7 BUY and 5 SELL insider trades, representing the acquisition of 64,693 and the disposition of 60,000 shares. Over the last 12 months, there were 16 BUYs and 16 SELLs from insiders. Insiders purchased 418,839 shares during that period but sold 594,508.
In the most recent transaction, Mehta Vimal sold 30,000 shares of BTAI for 20.18 per share on Jun 16. After the transaction, the CEO and President now owns 39,903 company shares. In a previous transaction on Jun 15, Mehta Vimal sold 30,000 shares at 21.54 per share. BTAI shares that CEO and President owns now total 39,903.
Among the insiders who sold shares, Mehta Vimal disposed of 6,500 shares on May 22 at a per-share price of $25.79. This resulted in the CEO and President holding 37,294 shares of BTAI after the transaction. In another insider transaction, Steinhart Richard I sold 5,000 shares at $27.17 per share on May 15. Company shares held by the Chief Financial Officer now total 1,500.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for BTAI in the last 3 months, the mean price target is $12.63 with high estimates of $31.00 and low estimates of $4.00. In terms of 52-week highs and lows, BTAI has a high of $34.12 and a low of $3.31.
As of this writing, BTAI has an earnings estimate of -$1.31 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$1.9. The company reported an EPS of -$1.84 in the last quarter, which was -13.60% lower than expectations of -$1.62.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BTAI’s latest balance sheet shows that the firm has $232.97M in Cash & Short Term Investments as of fiscal 2021. There were $1.40M in debt and $16.67M in liabilities at the time. Its Book Value Per Share was $0.20, while its Total Shareholder’s Equity was $221.67M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BTAI is Buy with a score of 4.00.